A practical reference on peptide purity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
=== Heart attacks after use of Vioxx === In 1999, the U.S. Food and Drug Administration (FDA) approved Vioxx (known generically as rofecoxib), a Merck product for treating arthritis. Vioxx was designed as a selective inhibitor of the enzyme cyclooxygenase-2. Such compounds were expected to cause less gastrointestinal bleeding than older anti-inflammatory drugs such as naproxen, which were associated with 20,000 hospitalizations and 2000 deaths each year. Vioxx became one of the most prescribed drugs in history. Thereafter, studies by Merck and by others found an increased risk of heart attack associated with Vioxx use when compared with naproxen. Merck adjusted the labeling of Vioxx to reflect possible cardiovascular risks in 2002. On September 23, 2004, Merck received information about results from a clinical trial it was conducting that included findings of increased risk of heart attacks among Vioxx users who had been using the medication for over eighteen months. On September 28, 2004, Merck notified the FDA that it was voluntarily withdrawing Vioxx from the market, and it publicly announced the withdrawal on September 30. An analysis for the period 1999–2004, based on U.S. Medical Expenditure Survey data, reported that Vioxx was associated with 46,783 heart attacks in the US, and along with the other popular COX-2 inhibitor Celebrex, an estimated 26,603 deaths from both. About 50,000 people sued Merck, claiming they or their family members had suffered medical problems such as heart attacks or strokes after taking Vioxx.
The Meeting of Teano between Garibaldi and King Victor Emmanuel II of Savoy took place on 26 October 1860, where he annexed Mezzogiorno. On 19 August 1860, Calabria was invaded from Sicily by Giuseppe Garibaldi and his Redshirts as part of the Expedition of the Thousand. Through King Francesco II of Naples had dispatched 16,000 soldiers to stop the Redshirts, who numbered about 3,500, after a token battle at Reggio Calabria won by the Redshirts, all resistance ceased and Garibaldi was welcomed as a liberator from the oppressive rule of the Bourbons wherever he went in Calabria. Calabria together with the rest of the Kingdom of Naples was incorporated in 1861 into the Kingdom of Italy. Garibaldi planned to complete the Risorgimento by invading Rome, still ruled by the pope protected by a French garrison, and began with semi-official encouragement to raise an army. Subsequently, King Victor Emmanuel II decided the possibility of war with France was too dangerous, and on 29 August 1862 Garibaldi's base in the Calabrian town of Aspromonte was attacked by the Regio Esercito. The Battle of Aspromonte ended with the Redshirts defeated with several being executed after surrendering while Garibaldi was badly wounded. With the plebiscite of 21 October 1860, Calabria and the other southern provinces became part of the Kingdom of Sardinia: consequently, elections were called to allow the newly annexed territories to select representation in Parliament. The election was held on 27 January 1861, and the new Parliament was inaugurated in Turin on February 18.
=== Early history (2017–2020) === Hims, Inc. was founded in November 2017 by Andrew Dudum, Jack Abraham, and Hilary Coles as part of Atomic Labs, a San Francisco venture studio co-founded by Dudum and Abraham. It initially offered generic prescription treatments for erectile dysfunction and hair loss alongside skincare products, marketed to millennial men through a direct-to-consumer brand. Hims received $7 million in seed funding from investors including Kirsten Green of Forerunner Ventures and Josh Kushner's Thrive Capital. In 2018, Hims launched Hers, a brand targeting women's health needs including birth control, skincare, and hair regrowth treatments. In January 2019, Hims raised $100 million in a Series C funding round at a $1 billion pre-money valuation. Later that year, the company expanded internationally with a launch in the United Kingdom. In April 2020, amid the COVID-19 pandemic, Hims & Hers expanded into mental health with a rollout of free anonymous group therapy sessions, later adding online psychiatry consultations and, in 2021, individual teletherapy services.
Sources: en.wikipedia.org
=== Mental health and mood disorders === Since the 1950s, over 150 published articles have found a positive outcome in using cranial electrostimulation (CES) to treat depression, anxiety, and insomnia.
Historically, American black bears occupied the majority of North America's forested regions. Today, they are primarily limited to sparsely settled, forested areas. American black bears currently inhabit much of their original Canadian range, though they seldom occur in the southern farmlands of Alberta, Saskatchewan and Manitoba; they have been extirpated on Prince Edward Island since 1937. Surveys taken in the mid-1990s found the Canadian black bear population to be between 396,000 and 476,000 in seven provinces; this estimate excludes populations in New Brunswick, the Northwest Territories, Nova Scotia and Saskatchewan. All provinces indicated stable populations of American black bears over the 2000s. The current range in the United States is constant throughout most of the Northeast and within the Appalachian Mountains almost continuously from Maine to northern Georgia, the northern Midwest, the Rocky Mountain region, the West Coast and Alaska. However, it becomes increasingly fragmented or absent in other regions. Despite this, American black bears in those areas seem to have expanded their range in recent decades, such as with sightings in Ohio, Illinois, southern Indiana, and western Nebraska. Sightings of itinerant black bears in the Driftless Area of southeastern Minnesota, northeastern Iowa, and southwestern Wisconsin are common.
On 17 October 1970 Rose gave birth to their first child, a daughter they named Heather Ann. (Speculation remains that Heather may have been sired by Rose's own father.) Two months later, Fred was imprisoned for the theft of car tyres and a vehicle tax disc. He remained imprisoned until 24 June 1971. As he served this six-and-a-half-month sentence, Rose, having just turned 17, looked after the three girls, with Charmaine and Anne Marie being told to refer to Rose as their mother. According to Anne Marie, she and Charmaine were frequently subjected to extensive physical and emotional abuse throughout the time they lived under Rose's care at Midland Road. Although Anne Marie was generally submissive and prone to display emotion in response to the abuse, Charmaine repeatedly infuriated Rose by her stoic refusal to either cry or display any sign of grief or servitude, no matter how severely she was treated. Despite the years of neglect and abuse, Charmaine's spirit had not been broken and she talked wistfully to Anne Marie of the belief she held that "mummy will come and save me." Anne Marie later recollected her sister repeatedly antagonised Rose by making statements such as, "My real mummy wouldn't swear or shout at us," in response to Rose's scathing language.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.